RT Journal Article
SR Electronic
T1 Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 61
DO 10.1186/s40425-017-0259-9
VO 5
IS 1
A1 Raphael B. Moreira
A1 Lana Hamieh
A1 Evisa Gjini
A1 Ana Lako
A1 Katherine M. Krajewski
A1 Charles H. Yoon
A1 Patrick A. Ott
YR 2017
UL http://jitc.bmj.com/content/5/1/61.abstract
AB Background Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen.Case presentation Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab.Conclusion The exact cause of our patient’s sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response.Abbreviations:COPDChronic Obstructive Pulmonary DiseaseCTComputerized tomographyCTLA-4Cytotoxic lymphocyte antigen-4FDAFood and Drug AdministrationMRIMagnetic Resonance ImagingPD-1Programmed death-1PD-L1Programmed death ligand 1PET/CTPositron emission tomography computerized tomographyT-VECTalimogene Laherparepvec